Product Overview

Cann Pharmaceutical Australia (CPA) has a large number of proprietary strains that are 100% organically cultivated and manufactured into proven phytocannabinoid pharmaceutical-grade drugs and treatments for specific medical conditions. All of CPA's strains conform to Therapeutic Goods (Standard for Medicinal Cannabis (TGO 93) Order 2017.

Medical conditions targeted by CPA's products include: Epilepsy, Autism, Palliative Care, PTSD and certain Cancers.

CPA has formulated a collection of THC and CBD ratios, available for sublingual administration. Depending on patient needs, CBD-rich or THC-rich ratios may be selected from.

For more information about these products, healthcare professionals should register to CPA's medical portal - which serves as an information hub for doctors, clinicians and other medical professionals in considering commencing prescription of medicinal cannabis for patients. Registration can be found in the bottom right corner of the menu bar.

Cann Pharmaceutical Australia
Level 1
The Realm
18 National Circuit
Barton ACT 2600
+61 2 6198 3253
  • LinkedIn
  • Facebook
  • Twitter
  • YouTube
Screen Shot 2021-02-08 at 3.34.34 pm cop
Screen Shot 2021-02-08 at 3.43.34 pm cop
The content on this website is not intended as a substitute for professional medical advice and/or as a recommendation and/or approval to use cannabis products, whether they are sold by the company or by another party.
© 2021 Cann Pharmaceutical Australia. All Rights Reserved.